Clinical Trials Browser

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Neoplasm Metastasis

Adenocarcinoma of Lung, Lung Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Non-Muscle Invasive Bladder Neoplasms

Cholangiocarcinoma

Resectable Intrahepatic Cholangiocarcinoma

Triple Negative Breast Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Advanced Biliary Tract Carcinoma

Hepato Cellular Carcinoma

Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Limited Stage Small Cell Lung Cancer

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Lung Neoplasms

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Adenocarcinoma, Stomach Neoplasms

Carcinoma, Hepatocellular, Liver Cirrhosis

Extensive Stage Small Cell Lung Cancer

Carcinoma, Hepatocellular

Non Small Cell Lung Cancer NSCLC

Urinary Bladder Neoplasms

Carcinoma, Hepatocellular

Non-small-cell Lung Cancer Patients

Cholangiocarcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Ovarian Epithelial

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

Breast Neoplasms, Inflammatory Breast Neoplasms

Adenocarcinoma of Lung, Lung Neoplasms

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CONVERGE

SLIDE-HCC

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

ENHANCE

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

TACTIC

IIT2025-03-YANG-LIFT-HCC

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

I-SPY

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

NeoCOAST-2

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

HAIC-quad

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

TIGOS-LS

DG-03

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

IPROC

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

TREMENDOUS-2

AUSTRAL

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

DIAMOND

ZENOBIA

WoO

VIRO-25

TRUDI

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Proton-STRIDE

ATRiBRAVE

PHOENIX